We fully acknowledge as stated in our discussion that apparent regression of retinopathy can result from a variety of causes including true regression of disease, changes in the retina that are not captured in retinal photographs and inaccuracy of the actual grading. However, as also noted in our discussion, when we constrained models to allow only misclassification and no actual regression, the model fit was not as good as when the model allowed for both misclassification and regression, so we do not think the regression noted in the paper is principally a result of issues with grading.
To the Editor: We thank Drs Stratton and Aldington for their comments on our paper. Our manuscript [1] was in the late stages of review at the time of the publication of their paper [2] .
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As stated in our paper [1] , the Scottish Diabetic Retinopathy Screening (DRS) programme has a centralised quality controlled grading system. This is comprised of grading centres all working to a single grading scheme with robust internal and external quality assurance. A high standard of quality controlled grading is essential for any screening programme. We embrace this, and have published data documenting our quality assurance results [3] , as cited in our paper [1] , and all screening centres in Scotland continue to undertake rigorous quality assurance within the programme.
In spring 2013, 84 graders from nine centres, including those using automated grading systems, participated in Scotland's biannual external quality assurance programme. At this time no cases of observable maculopathy, or observable background, referable background or proliferative retinopathy were misclassified as 'no retinopathy'. In cases where a grading of no retinopathy was recorded, the consensus standard was no retinopathy in 74.4% of cases, mild background in 13.2%, referable maculopathy in 0.1% and technical failure in 0.3%.
We also agree that all screening programmes, in general, and indeed any changes in the screening interval, should be closely monitored and that any programme switching to a longer interval for those with no evidence of disease at a previous examination would need to be confident in its grading criteria for 'no disease'.
As such, we are confident that the increased risk from lengthening screening intervals for diabetic retinopathy for patients with type 2 diabetes and no visible retinopathy at two successive annual screening exams is small, at least in Scotland, and expect that our study will help inform future decisions pertaining to the Scottish retinal screening programme.
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